{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination broadens tumor antigen presentation, including expansion of the MHC-I peptidome.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        }
      ],
      "caveat": "These antigen-presentation measurements come from preclinical mechanistic assays and may not generalize uniformly across all tumor models or human tumors."
    },
    {
      "claim_id": "C02",
      "claim": "Type I interferon signaling is a key mechanistic driver of the sensitization effect from intratumoral mRNA vaccination.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        },
        {
          "quote": "- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "The causal role of interferon signaling is supported by blockade experiments in the tested systems, but the magnitude and safety of interferon-driven inflammation could differ by tumor type and clinical context."
    },
    {
      "claim_id": "C03",
      "claim": "Intratumoral mRNA vaccination increases PD-L1 pathway activity and is associated with higher intratumoral CD8+ T-cell density, supporting combination with checkpoint blockade.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |",
          "line_ref": "L32"
        },
        {
          "quote": "| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |",
          "line_ref": "L33"
        },
        {
          "quote": "4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "Fold-changes in PD-L1 and CD8+ density do not alone establish clinical benefit; the relationship between these biomarkers and patient outcomes can vary across tumor types and treatment histories."
    },
    {
      "claim_id": "C04",
      "claim": "In a retrospective cohort of metastatic patients treated with ICIs, prior SARS-CoV-2 mRNA vaccination was associated with improved survival.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "- The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "Because the human comparison is observational with variable vaccination timing, it cannot establish that vaccination caused better survival; unmeasured differences between groups may explain part or all of the association."
    },
    {
      "claim_id": "C05",
      "claim": "Control conditions indicate that vaccine-only, ICI-only, and non-mRNA particle controls do not reproduce the full sensitization effect seen with the intended intervention.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "- Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
          "line_ref": "L36"
        },
        {
          "quote": "- ICI-only treatment had limited activity in low-immunogenic baseline settings.",
          "line_ref": "L37"
        },
        {
          "quote": "- Lipid particle controls lacking mRNA did not reproduce the sensitization effect.",
          "line_ref": "L38"
        }
      ],
      "caveat": "These null results are described at a high level and appear context-dependent (for example, in non-immunogenic or low-immunogenic settings), so they may not apply to all tumor models or clinical settings."
    }
  ]
}
